Skip to the shortlist
Peptide ClarityGuide
Question

Why people stop taking NMN, and what the research says

Feeling nothing is the most common reason people give for quitting NMN. The trials explain why that happens.

Mara Whitford

Heads up: Peptide Clarity Guide works with partners, and a few buttons below pay us if you join (you pay the same). Who pays plays no part in the order here, or in what we write. How we earn.

The short answer

The cited trials do not establish why most people stop NMN. They show increased blood NAD, with inconsistent changes in sleep, walking or questionnaire scores. Lack of noticeable benefit, cost and uncertainty are reasons someone might reassess use; they are not measured population-wide reasons for quitting.

Key takeaways

  • In placebo-controlled trials, NMN raised an NAD marker in the blood every time it was measured.
  • Benefits people could feel were mixed. Several trials found no change in body composition or insulin resistance.
  • The trials were small (11 to 108 people) and short (2 weeks to 12 weeks). Most had company ties.
  • No serious safety problem showed up in those short trials.
  • One small trial assigned morning or afternoon use; it did not establish a generally best time or a food strategy.

Here's the short version. NMN does what it says on the chemistry: it raises NAD, a molecule your cells use to make energy. Some trials report sleep or questionnaire improvements, but a reliable noticeable benefit is not established. These studies did not survey a representative group of people who stopped taking NMN, so they cannot tell us the most common reason for stopping.

The top reason: "I didn't feel anything"

The trials help explain this. NMN raises a blood marker, NAD, but most studies didn't find changes people would notice day to day.

In 80 healthy middle-aged adults, blood NAD rose in every NMN group by day 30 and stayed up at day 60. Insulin resistance, measured as HOMA-IR, didn't change [5]. In older Japanese men, NMN raised NAD but had no effect on body composition. Gains in walking speed and grip strength were only "nominally" significant, which the authors said need confirming in larger studies [3].

In 30 healthy adults over 12 weeks, NAD rose and lab tests stayed normal. Nothing else was reported to change [4]. A higher number on a blood test doesn't always mean you'll feel it.

What NMN did show in trials

Its clearest result is a rise in blood NAD. A few trials also found small secondary benefits.

  • Muscle insulin sensitivity. In 25 postmenopausal women with prediabetes, 10 weeks of NMN improved how well muscle responded to insulin. Body fat, blood pressure and blood lipids didn't change [2].
  • Walking. In 60 older adults, the main test (a stepping test) showed no difference after 12 weeks. A shorter 4-meter walking time was a secondary result [6].
  • The 6-minute walk. Walking distance rose more than on placebo in the 60-day trial of middle-aged adults [5].

Company ties sit next to most of these numbers. The 6-minute-walk trial was run by authors employed by two NMN makers, Abinopharm and ABA Chemicals [5]. The walking-time trial's authors work for Meiji [6]. The insulin study was funded by the NIH, but one author receives NMN patent-licensing fees [2]. For the fuller picture, see does NMN work?

NMN trials in people: what changed, and what didn't.
Trial (year)Who and how longBlood NADWhat else changedDidn't changeCompany ties
Yoshino (2021) [2]25 women with prediabetes, 10 weeksUp in blood cellsMuscle insulin sensitivityBody fat, blood pressure, lipidsNIH-funded; one author earns NMN patent fees
Igarashi (2022) [3]Healthy older men, 6 or 12 weeksUpGait speed, grip (nominal)Body compositionCo-authors from Mitsubishi Corporation Life Sciences
Okabe (2022) [4]30 healthy adults, 12 weeksUpNone reportedLab tests, vital signsCo-authors from Mitsubishi Corporation Life Sciences
Yi (2023) [5]80 healthy middle-aged adults, 60 daysUp, highest in the two top-dose groups6-minute walk, SF-36 health scoreInsulin resistance (HOMA-IR)Authors employed by Abinopharm and ABA Chemicals
Morifuji (2024) [6]60 older adults, 12 weeksUp4-meter walk time, sleep score (secondary)Stepping test (main outcome)Authors employed by Meiji
Pencina (2023) [7]32 adults aged 55 to 80, 14 daysUp, dose-relatedNot testedNot testedCo-authors listed at Metro International Biotech

All six were randomized and placebo-controlled. None measured aging, disease or lifespan.

People who got NMN or placebo in each trial
Yamaguchi 2024 (no placebo group)
11 people[9]
Yoshino 2021
25 people[2]
Okabe 2022
30 people[4]
Pencina 2023
32 people[7]
Morifuji 2024
60 people[6]
Yi 2023
80 people[5]

Side effects people report

In short trials, NMN didn't cause more problems than placebo. Online reports mention stomach upset or sleep changes, which trials haven't confirmed.

One cited safety study tested 1,250 mg daily for up to 4 weeks in 31 healthy adults. The trial used that amount to look for harm. It found no changes beyond normal day-to-day variation in blood, urine or body measurements, and no severe adverse events [8]. That study was funded by an NMN supplier. More on this in is NMN safe?

Cost adds up when you can't see a benefit

NMN is an out-of-pocket supplement cost every month. Some people stop when they can't point to a benefit that justifies the spend.

That math changes if you're paying for NAD+ itself through a clinic, which is a different product with its own costs. See NMN and NAD+ together for how the two differ.

The US rules flipped twice in three years

FDA said in 2022 that NMN couldn't be sold as a supplement, then reversed itself in September 2025. For almost three years, people buying it couldn't tell where it stood.

On October 11, 2022, FDA wrote to a company that had filed an NMN ingredient notice, saying NMN was excluded from the dietary-supplement definition. It sent similar letters to every firm that had filed one. Industry groups petitioned. On September 29, 2025, FDA answered: "we now conclude that NMN is not excluded from the dietary supplement definition" [11].

NMN is no longer excluded under that provision; each product still has to meet other supplement requirements. It's still not an FDA-approved drug. For the full status story, see is NMN legit?, and for what to look for on a label, where to buy NMN.

Is NMN worth taking? Depends what you want from it

The evidence supports "raises NAD." It doesn't yet support "slows aging" or "more energy."

A 2026 systematic review of 33 human studies of NAD boosters says the same. Oral NMN and NR reliably raise NAD markers, but effects on function and health outcomes were "heterogeneous and often null" [10]. If energy is your real goal, our energy shortlist starts with what's been tested for it. Your clinician can weigh NMN against your health and medicines.

How the trials gave NMN

The cited trials used oral NMN in different regimens and formulations. A small trial examined morning and afternoon use, but an optimal time is not established [1].

One small open-label study had 11 Japanese men take two capsules once daily before breakfast for 8 weeks. NAD in their blood cells rose [9]. That's a description of one study's setup, not a recommendation. A separate small trial examined morning and afternoon use; it does not establish a universal schedule or a food strategy [1]. Follow the product's own directions and ask your clinician, especially if you take other medicines.

What happens when you stop: no evidence of a rebound

These trials measured people while they were taking NMN. None was built to test what happens after stopping, so there's no evidence of a rebound or withdrawal effect either way.

If you've stopped and want to know what a longer course might have shown, see how long NMN takes to work. Start there, then take your questions to a clinician.

Frequently asked

Why did I feel nothing on NMN?
That matches the trials. NMN raised blood NAD, but most studies found few changes people would notice. The benefits that did appear were small and often secondary results.
Should I take NMN?
That's a question for your own clinician, based on your health and medicines. So far the evidence supports a rise in NAD levels, not proven health outcomes.
Is it better to take NMN in the morning or at night?
A small trial examined morning and afternoon use, but an optimal time is not established. The trials gave it once daily by mouth. Follow the product's directions and ask your clinician.
Can NMN keep you awake?
Trials haven't shown that. One 12-week study in older adults reported better sleep-quality scores as a secondary result. If you notice a change, talk to your clinician.
Is NMN worth the money?
If you want proven effects on aging or energy, the evidence isn't there yet. If you want to raise NAD levels, the trials show it does that.

Sources

  1. [1] Kim M. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study (2022). PMID 35215405
  2. [2] Yoshino M. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (2021). PMID 33888596
  3. [3] Igarashi M. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men (2022). PMID 35927255
  4. [4] Okabe K. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects (2022). PMID 35479740
  5. [5] Yi L. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial (2023). PMID 36482258
  6. [6] Morifuji M. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study (2024). PMID 38789831
  7. [7] Pencina KM. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults (2023). PMID 35182418
  8. [8] Fukamizu Y. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women (2022). PMID 36002548
  9. [9] Yamaguchi S. Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men (2024). PMID 38191197
  10. [10] Gallagher C. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence (2026). PMID 41655607
  11. [11] FDA response letter to the Natural Products Association and Alliance for Natural Health USA on NMN, docket FDA-2023-P-0872 (September 29, 2025) (2025). FDA

Related research